Mucomycoses identified using the COVID-19 health impacts with mucomycoses consider the COVID-19

Objective: The study's participants had mucormycosis associated with the coronavirus disease 2019 (COVID-19), and the researchers sought to describe their clinical characteristics, risk factors, and ultimate findings (CAM). Study Design: A Multi-center Study. Place and Duration: NTH AND HMC hospital Peshawar. Duration July 2019 to July 2020. Methods: Overall, this research included 180 cases in which both sexes showed signs of mucormycosis during the pandemic coronavirus outbreak of 2016. Patients were between the ages of 22 and 80. After obtaining written permission from each patient, demographic information such as age, sex, BMI, and illness duration was gathered. Patients were hospitalized in COVID-19 emergency ward and underwent RT-PCR and MRIs. Mucormycosis was examined for its comorbidities, symptoms, and etiology. End-of-study death rates, hospitalizations, and admissions to intensive care units were all tallied up. To analyze the complete dataset, the SPSS 20.0 version was used. Result: There were 130 men and 50 females in the study population (26.6 percent ). The patients had a mean age of 52.44 years and a mean BMI of 27.74 kg/m2. In this research, 54 (62.2 percent) patients had COVID-19, and 35 (38.9 percent) had coronavirus. 